O. Benbrahim

发表

The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments

O. Decaux, J. Viallard, F. Bauduer, 2018, Hematology.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

P. Cony-Makhoul, L. Knoops, V. Ugo, 2017, Haematologica.

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

C. Haioun, Isabelle Gasnereau, P. Solal-Céligny, 2017, Clinical lymphoma, myeloma & leukemia.

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

P. Cony-Makhoul, S. de Botton, P. Rousselot, 2018, Leukemia & lymphoma.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

S. Leprêtre, A. Delmer, S. Choquet, 2019, Leukemia & lymphoma.

A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy‐associated secondary immunodeficiency

O. Decaux, J. Viallard, F. Bauduer, 2018, European Journal of Haematology.

Compliance with ASCO 2006 recommendations for the use of "white blood cell growth factors" in advanced lung cancer (LC) or breast cancer (BC) or non-Hodgkin lymphoma (NHL): An interim analysis of French National Observational Study—The ZOHé study.

C. Haioun, P. Solal-Céligny, H. Roché, 2014 .

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

K. Tarte, R. Houot, L. Xerri, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

B. Pégourié, P. Moreau, M. Macro, 2017 .

[Use of intravenous and subcutaneous human immunoglobulins].

P. Chérin, P. Cherin, O. Benbrahim, 2019, Soins; la revue de reference infirmiere.